Question 1

What is INmune Bio?

Accepted Answer

INmune Bio is a Company.

Question 2

How often does INmune Bio appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was INmune Bio first tracked by Ergen?

Accepted Answer

First tracked on Jun 25, 2026.

Question 4

When was INmune Bio last mentioned in news?

Accepted Answer

Last active on Jun 25, 2026.

Question 5

What is INmune Bio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is INmune Bio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving INmune Bio?

Accepted Answer

MHRA Approves INmune Bio Ebstrocel PIP (Jun 25, 2026, 6 articles).

Question 8

How did the "MHRA Approves INmune Bio Ebstrocel PIP" event impact INmune Bio?

Accepted Answer

INmune Bio Inc. received approval for its Pediatric Investigation Plan (PIP) for Ebstrocel, accelerating its regulatory path in the United Kingdom and de-risking its CORDStrom platform. This positions the company for potential market authorization and commercialization, creating a significant value opportunity for shareholders.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.